During the last session, CureVac N.V. (NASDAQ:CVAC)’s traded shares were 0.38 million. At the end of the trading day, the stock’s price was $15.66, reflecting an intraday gain of 2.96% or $0.45. The 52-week high for the CVAC share is $125.66, that puts it down -702.43 from that peak though still a striking 9.32% gain since the share price plummeted to a 52-week low of $14.20. The company’s market capitalization is $3.09B, and the average trade volume was 537.83K shares over the past three months.
CureVac N.V. (CVAC) received a consensus recommendation of a Hold from analysts. That translates to a mean rating of 3.20. CVAC has a Sell rating from 1 analyst(s) out of 6 analysts who have looked at this stock. 2 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it. 1 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be $0.
CureVac N.V. (NASDAQ:CVAC) trade information
CureVac N.V. (CVAC) registered a 2.96% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 2.96% in intraday trading to $15.66 this Friday, 05/13/22, hitting a weekly high. The stock’s 5-day price performance is 0.13%, and it has moved by -15.31% in 30 days. Based on these gigs, the overall price performance for the year is -85.76%.
The consensus price target of analysts on Wall Street is $27.73, which implies an increase of 43.53% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $16.17 and $49.29 respectively. As a result, CVAC is trading at a discount of -214.75% off the target high and -3.26% off the low.
CureVac N.V. (CVAC) estimates and forecasts
In the rating firms’ projections, revenue will increase 52.50% compared to the previous financial year.
Revenue for the current quarter is expected to be $11.3 million as predicted by 2 analyst(s). Meanwhile, a consensus of 2 analyst(s) estimates revenue growth to $25.32 million by the end of Jun 2021.
While earnings are projected to return -207.50% in 2022.
CureVac N.V. is due to release its next quarterly earnings on November 18. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
CureVac N.V. (NASDAQ:CVAC)’s Major holders
CureVac N.V. insiders own 55.05% of total outstanding shares while institutional holders control 24.02%, with the float percentage being 53.45%. Baillie Gifford and Company is the largest shareholder of the company, while 173 institutions own stock in it. As of Dec 30, 2021, the company held over 3.92 million shares (or 2.10% of all shares), a total value of $134.61 million in shares.
The next largest institutional holding, with 3.13 million shares, is of Bill & Melinda Gates Foundation’s that is approximately 1.68% of outstanding shares. At the market price on Dec 30, 2021, these shares were valued at $107.55 million.
Also, the Mutual Funds coming in first place with the largest holdings of CureVac N.V. (CVAC) shares are Vanguard International Growth Fund and Price (T.Rowe) Health Sciences Fund. Data provided on Nov 29, 2021 indicates that Vanguard International Growth Fund owns about 2.73 million shares. This amounts to just over 1.46 percent of the company’s overall shares, with a $131.73 million market value. The same data shows that the other fund manager holds slightly less at 0.41 million, or about 0.22% of the stock, which is worth about $22.17 million.